# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0001193125-25-265702
Filing Date
2025-11-05
Accepted
2025-11-05 07:03:12
Documents
13
Period of Report
2025-11-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 8-K | lrmr-20251105.htm iXBRL | 8-K | 48155
2 | EX-99.1 | lrmr-ex99_1.htm | EX-99.1 | 183905
3 | GRAPHIC | img46574298_0.jpg | GRAPHIC | 282533
4 | GRAPHIC | img46574298_1.jpg | GRAPHIC | 282533
| Complete submission text file | 0001193125-25-265702.txt |  | 1080404

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | lrmr-20251105.xsd | EX-101.SCH | 23893
15 | EXTRACTED XBRL INSTANCE DOCUMENT | lrmr-20251105_htm.xml | XML | 4533

Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

EIN.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36510 | Film No.: 251451725
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)